TerminatedNCT05342350
International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy
Studying Adult hepatocellular carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Johns Hopkins University
- Principal Investigator
- Doan Dao, MD, M.D., Ph.DJohns Hopkins University
- Intervention
- GALAD Score(other)
- Enrollment
- 360 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2025
Study locations (10)
- King Faisal Specialist Hospital and Research Center in Jeddah, Jeddah, Saudi Arabia
- National Guard Hospital in Jeddah, Jeddah, Saudi Arabia
- King Faisal Specialist Hospital and Research Centre in Riyadh, Riyadh, Saudi Arabia
- King Saud University Medical Center, Riyadh, Saudi Arabia
- National Guard Hospital in Riyadh, Riyadh, Saudi Arabia
- Binh An Hospital, Rach Gia, Kien Giang, Vietnam
- Medic Ca Mau, Cà Mau, Vietnam
- Dong Da Hospital, Hà Nội, Vietnam
- Institute of Gastroenterology and Hepatology, Hà Nội, Vietnam
- Medic Medical Center-Ho Chi Minh City, Ho Chi Minh City, Vietnam
Collaborators
King Faisal Specialist Hospital & Research Center · Medic Medical Center (Viet Nam)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05342350 on ClinicalTrials.govOther trials for Adult hepatocellular carcinoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE2NCT07441369Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases CancerFudan University
- RECRUITINGPHASE2NCT07175441Evaluation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Participants With Advanced Unresectable Hepatocellular CarcinomaRiboscience, LLC.
- RECRUITINGPHASE2NCT07560488Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular CarcinomaTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE1, PHASE2NCT07291076A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)Bristol-Myers Squibb
- RECRUITINGPHASE2NCT07010497A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular CarcinomaAsan Medical Center
- RECRUITINGPHASE1, PHASE2NCT07500220Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCCBeijing Biotech
- RECRUITINGPHASE2NCT07413354Tislelizumab Combined With Huaier Granule as First-line Treatment for Unresectable Hepatocellular CarcinomaTongji Hospital
- RECRUITINGNANCT07365527Sonoporation and Tumor Microenvironment Response in Colorectal Liver MetastasesZealand University Hospital